Title: Efficacy of adefovir dipivoxil in treating patients with hepatitis B resistant to lamivudine
Abstract: AIM:To evaluate the efficacy and safety of adefovir dipivoxil in treating patients with hepatitis B resistant to lamivudine. METHODS: 68 patients with hepatitis B resistant to lamivudine were administered 10 mg adefovir dipivoxil orally daily for over 1 years.The serum HBV-DNA levels were measured by quantitative PCR and liver function test,HBeAg/anti-HBe and safety assessments were also performed at 0,12,24,52 weeks after treatment. RESULTS: After 12,24,52 weeks of treatment, the mean HBV-DNA levels were reduced by 1.6 lg copies/mL (t=10.10,P0.01), 2.9 lg copies/mL (t=13.01,P0.01) and 4.5 lg copies/mL(t=14.08, P0.01). The normalization rates of ALT levels were 19.12%,48.53% and 70.59%. The HBeAg loss rates were 0%, 19.44% and 47.22%. The HBV-DNA undetectable rates were 4.41%, 19.12% and 54.41% respectively. CONCLUSION: Adefovir dipivoxil is effective and safe for treating chronic hepatitis B patients with lamivudine resistance.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot